AQEMIA
Alessio Prunotto is a computational chemist with expertise in in silico drug discovery, currently working at Aqemia since February 2022. Prior experience includes a postdoctoral researcher position at the University of Lausanne, where a computational method was developed for assessing ligand poses and protein-ligand interactions, and a PhD at EPFL focused on the molecular mechanisms of drug-resistant bacteria using molecular dynamics simulations. Additional roles include scientific assistant at EPFL, research assistant at the University of Applied Sciences and Arts of Southern Switzerland, visiting scientist at the Institute of Molecular and Cell Biology of Rosario, and a visiting student at the University of Alberta. Alessio holds a PhD in Computational Biology from EPFL and master's and bachelor's degrees in Bioengineering and Biomedical Engineering from Politecnico di Torino.
This person is not in any teams
This person is not in any offices
AQEMIA
4 followers
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. AQEMIA is based in Paris and London.